Advances in Recurrent/Metastatic Nasopharyngeal Carcinoma: Immunotherapy and Biomarkers
Released On
October 7, 2024
Expires On
October 7, 2025
Media Type
Internet
Completion Time
30 Minutes
Specialty
Hematology-Oncology, Pharmacy, Radiology, Surgery
Topic(s)
Oncology, Radiology, Surgery
In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is supported by an educational grant from Coherus BioSciences.
Credit Available
- Physicians — maximum of 0.5 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity was developed for medical oncologists, head and neck surgeons, radiation oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients diagnosed with metastatic nasopharyngeal carcinoma (NPC).
Program Overview
Greater understanding of the tumor microenvironment of nasopharyngeal carcinoma (NPC) has led to the introduction of immunotherapy into the NPC treatment landscape. Incorporating immunotherapy has changed the current standard of care in the treatment of recurrent and metastatic NPC. Robert Ferris, MD, explores clinical trial data leading to approval of PD-1 inhibitors both as monotherapy and in combination with chemotherapy. He also delves into the significance of biomarkers that may influence prognosis and management of patients with NPC, as well as managing toxicity related to PD-1 inhibitors.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Design evidence-based treatment plans for patients with NPC who are appropriate candidates for immunotherapy.
- Describe the safety and efficacy of immunotherapy for patients with NPC.
- Employ appropriate biomarker testing to guide prognosis and management of patients with NPC.
- Develop appropriate collaborative strategies among the multidisciplinary and interprofessional care team to prevent, identify, and mitigate toxicities related to immunotherapy for the treatment of patients with NPC.
Faculty
Robert Ferris, MD, PhD
Director, UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Accreditation Statement
In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit
The Annenberg Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
- Robert Ferris, MD, PhD
- Advisory Board: Adaptimmune, Bristol-Myers Squibb, Coherus BioSciences, Inc., CureVac, Eisai Europe Limited, Genmab, Hookipa Biotech GmbH, Instil Bio, Inc, Lifescience Dynamics Limited, MacroGenics, Inc., MeiraGTx, LLC, Merck, Merus NV, Numab Therapeutics AG, OncoCyte Corporation, Pfizer, Rakuten Medical, Inc, Regeneron, Seagen, Inc, SIRPant Immunotherapeutics, Inc, Vir Biotechnology, Inc
- Board of Directors:: CytoAgents
- Consultant: Adagene Incorporated, Aduro Biotech, Inc., Bicara Therapeutics, Inc, Brooklyn ImmunoTherapeutics LLC, Catenion, EMD Serono, Everest Clinical Research Corporation, F. Hoffmann-La Roche Ltd, Federation Bio, Inc, Genocea Biosciences, Inc, Kowa Research Institute, Inc., Mirati Therapeutics, Inc, Nanobiotix, Novartis Pharmaceutical Corporation, Novasenta, PPD Development, L.P., Sanofi, Zymeworks, Inc.
- Data Safety Monitoring Board: : Mirror Biologics, Inc.
- Research Support: : Bristol-Myers Squibb, AstraZeneca/MedImmune, Novasenta, Tesaro
The following have no significant relationship to disclose:
Rachel Feaster, PharmD (Medical Writer)
Annenberg Center for Health Sciences
All staff at the Annenberg Center have no relevant financial relationships to disclose.
All the relevant financial relationships listed for these individuals have been mitigated.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Read or Review the activity content.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For help or questions about this activity please contact Continuing Education: [email protected].